SAN RAFAEL, Calif., Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and ...

BioMarin (BMRN) announced positive new data from studies of Voxzogo in children with achondroplasia and in ongoing clinical trials ...

In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), ...

We recently published a list of Paul Singer’s Latest Portfolio: Top 10 Stock Picks. In this article, we are going to take a ...

EverSource Wealth Advisors LLC lowered its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 91.1% in the ...

Investors in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) had a good week, as its shares rose 9.7% to close at US$71.17 following the release of its yearly results. BioMarin Pharmaceutical reported ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical has a twelve month low of $60.63 and a twelve month high of $94.85. The stock has a market cap of $13.56 billion, a price-to-earnings ratio of 32.35, a P/E/G ratio of 0.61 ...

Fintel reports that on February 24, 2025, Oppenheimer upgraded their outlook for BioMarin Pharmaceutical (NasdaqGS:BMRN) from Perform to Outperform. Analyst Price Forecast Suggests 44.46% Upside ...